erlotinib hydrochloride has been researched along with Triple Negative Breast Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F | 1 |
| Accordino, MK; Crew, KD; Fenn, K; Hershman, DL; Kalinsky, K; Lee, SM; Maurer, M; Trivedi, MS | 1 |
| Broude, EV; Kassler, S; Lim, CU; McDermott, MSJ; Melendez, T; Munie, J; Sharko, AC | 1 |
| Anstine, LJ; Bryson, BL; Finke, VS; Keri, RA; Majmudar, PR; Roberts, MS; Seachrist, DD; Webb, BM; Weber-Bonk, KL | 1 |
| Irurzun-Arana, I; McDonald, TO; Michor, F; Trocóniz, IF | 1 |
| Chien, YC; Huang, WC; Hung, CC; Liu, LC; Tsai, IC; Wu, JY; Yu, YL | 1 |
| Adorno-Cruz, V; Chang, YF; Cristofanilli, M; Dashzeveg, NK; El-Shennawy, L; Jia, Y; Kawaguchi, M; Liu, H; Liu, X; Patel, D; Ramos, EK; Schuster, EJ; Taftaf, R; Zhang, Y | 1 |
| Camorani, S; Cerchia, L; Crescenzi, E; Fedele, M; Gramanzini, M; Zannetti, A | 1 |
| Jafari, M; Kennell, C; Lee, JH; Lee, JY; Ruiz-Torres, SJ; Waltz, SE; Zhou, Z | 1 |
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Anborgh, PH; Chambers, AF; Lee, DJ; Stam, PF; Tuck, AB | 1 |
| Chen, JL; Chen, YT; Chu, PY; Dai, MS; Huang, CT; Huang, TT; Lau, KY; Liu, CY; Shiau, CW; Tseng, LM; Wang, WL | 1 |
| Anderson, J; Baker, K; Gadi, V; Garrison, M; Gralow, J; Jenkins, I; Korde, L; Kurland, B; Linden, H; Redman, M; Rodler, E; Smith, J; Specht, J; Symonds, L; Van Haelst, C; Wu, QV | 1 |
| Fu, J; Lin, Y; Liu, C; Lu, G; Lu, Z; Wan, X | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Choi, JS; Choi, YL; Jung, K; Kim, YJ; Kundu, J; Kwon, MJ; Lee, SE; Oh, E; Seo, J; Shin, YK; Song, JY | 1 |
| Ding, D; Hu, JL; Liu, XP; Ren, H; Wang, JG; Yang, WL; Yu, J; Zhang, L | 1 |
| Boerner, JL; Christensen, JG; Essenburg, CJ; Graveel, CR; Korkaya, H; Linklater, ES; Madaj, Z; Maroun, CR; Melnik, MK; Steensma, MR; Tovar, EA; Turner, L; Winn, ME | 1 |
| Chen, KF; Chen, MH; Hu, MH; Huang, CT; Huang, TT; Lau, KY; Lee, CH; Liu, CY; Shiau, CW; Tsai, WC; Tseng, LM; Wang, DS; Wang, WL; Yang, HP | 1 |
| Collignon, J; Delvenne, P; Donneau, AF; Feyereisen, E; Foidart, P; Gofflot, S; Jerusalem, G; Lienard, M; Noël, A; Schroeder, H; Somja, J; Sounni, NE; Truong, A; Yip, C | 1 |
| Bao, B; Boerner, JL; Bollig-Fischer, A; Dyson, G; Farr, RL; Girsch, E; Marchetti, L; Mitrea, C; Mohammad, R; Terlecky, SR; Wijesinghe, P | 1 |
2 trial(s) available for erlotinib hydrochloride and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MAP Kinase Signaling System; Maximum Tolerated Dose; Metformin; Middle Aged; Progression-Free Survival; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2020 |
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Tubulin Modulators | 2019 |
19 other study(ies) available for erlotinib hydrochloride and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2022 |
CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; MCF-7 Cells; Phenylenediamines; Protein Kinase Inhibitors; Pyrimidines; Repressor Proteins; Survival Analysis; Trans-Activators; Triple Negative Breast Neoplasms | 2020 |
KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Phosphorylation; Signal Transduction; Triple Negative Breast Neoplasms | 2020 |
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinolines; Software; Thiazoles; Triple Negative Breast Neoplasms | 2020 |
Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Triple Negative Breast Neoplasms; Xanthophylls | 2021 |
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cell Aggregation; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, Reporter; Humans; Hyaluronan Receptors; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Neoplasm Proteins; Neoplastic Cells, Circulating; Neoplastic Stem Cells; RNA; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
Topics: Animals; Aptamers, Nucleotide; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Integrin alphaVbeta3; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NIH 3T3 Cells; Protein Binding; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Erlotinib Hydrochloride; Female; Humans; Lactates; Mice; Mice, Transgenic; Nanoparticles; Neoplasms, Experimental; Polyethylene Glycols; Triple Negative Breast Neoplasms | 2017 |
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Molecular Targeted Therapy; Osteopontin; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Topics: Animals; Apoptosis; Autoantigens; Cell Line, Tumor; Cell Survival; Cisplatin; Disease Models, Animal; DNA-Binding Proteins; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Models, Biological; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cell-Penetrating Peptides; Diamines; Drug Carriers; Drug Liberation; Erlotinib Hydrochloride; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oligopeptides; Receptors, Notch; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfones; Triple Negative Breast Neoplasms | 2014 |
Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Neurokinin-1; RNA Interference; RNA, Small Interfering; Signal Transduction; Substance P; Triple Negative Breast Neoplasms | 2015 |
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor Cross-Talk; Signal Transduction; Triple Negative Breast Neoplasms | 2016 |
EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; ets-Domain Protein Elk-1; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Mice, Nude; RNA, Messenger; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2017 |
MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Matrix Metalloproteinases, Membrane-Associated; Mice; Mice, Nude; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.
Topics: Antioxidants; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Triple Negative Breast Neoplasms | 2017 |